Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
An assay recapitulating the 3' processing activity of HIV-1 integrase (IN) was used to screen the Boehringer Ingelheim compound collection. Hit-to-lead and lead optimization beginning with compound 1 established the importance of the C3 and C4 substituent to antiviral potency against viruses with different aa124/aa125 variants of IN. The importance of the C7 position on the serum shifted potency was established. Introduction of a quinoline substituent at the C4 position provided a balance of potency and metabolic stability. Combination of these findings ultimately led to the discovery of compound 26 (BI 224436), the first NCINI to advance into a phase Ia clinical trial.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although ALLINIs have yet to advance in clinical trials, several compounds display exquisite low-nM potencies to inhibit HIV-1 replication in vitro172,180,182,183.”
From Structure and function of retroviral integrase (2022) · cites this paper as [172]
In the citing paper
“Many ALLINIs were co-crystallised with the isolated HIV-1 IN CCD, and the structures revealed the molecules grip onto the LEDGF/p75 IBD binding pocket at the IN CCD dimerization interface171,172,174,175,180,186,187.”
From Structure and function of retroviral integrase (2022) · cites this paper as [172]
In the citing paper
“Lead compounds in this class were discovered using two very different high-throughput approaches: a screen for inhibitors of HIV-1 IN 3’-processing activity172, and structure-based design of small molecule inhibitors of the HIV-1 IN-LEDGF/p75 interaction171.”
From Structure and function of retroviral integrase (2022) · cites this paper as [172]
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Adverse effects of antiretroviral therapy
Carr, A., & Cooper, D. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02854-3 · Cited by 1,057
Dyda, F., Hickman, A. B., Jenkins, T. M., Engelman, A., Craigie, R., & Davies, D. R. (1994) · Science · doi:10.1126/science.7801124 · Cited by 810
Clavel, F., & Hance, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejm2ra025195 · Cited by 800
LEDGF/p75 Is Essential for Nuclear and Chromosomal Targeting of HIV-1 Integrase in Human Cells
Maertens, G., Cherepanov, P., Pluymers, W., Busschots, K., De Clercq, E., Debyser, Z., & Engelborghs, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303594200 · Cited by 493
Christ, F., Voet, A., Marchand, A., Nicolet, S., Desimmie, B. A., Marchand, D., Bardiot, D., Van der Veken, N. J., Van Remoortel, B., Strelkov, S. V., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.370 · Cited by 479
Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75
Cherepanov, P., Ambrosio, A. L. B., Rahman, S., Ellenberger, T., & Engelman, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506924102 · Cited by 408
Jurado, K. A., Wang, H., Slaughter, A., Feng, L., Kessl, J. J., Koh, Y., Wang, W., Ballandras-Colas, A., Patel, P. A., Fuchs, J. R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300703110 · Cited by 203
Multimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors
Kessl, J. J., Jena, N., Koh, Y., Taskent-Sezgin, H., Slaughter, A., Feng, L., de Silva, S., Wu, L., Le Grice, S. F. J., Engelman, A., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.354373 · Cited by 182
Christ, F., Shaw, S., Demeulemeester, J., Desimmie, B. A., Marchand, A., Butler, S., Smets, W., Chaltin, P., Westby, M., Debyser, Z., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00717-12 · Cited by 176
Research works printed but not linked: 5
- Clavel F., 2004, N. Engl. J. Med., 350, 1023, 10.1056/nejmra025195 · doi:10.1056/nejmra025195 · Paper page
- Arribas J. R., 2013, Curr. Opin. HIV AIDS, 8, 341
- aFenwick, C.; Bethell, R.; Bonneau, P.; Duan, J.; Faucher, A.M.; Mason, S.; Poupart, M.A.; Simoneau, B.; Tsantrizos, Y.; Yoakim, C.Identification of BI-C, a novel HIV-1 non-catalytic site integrase inhibitor.18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 27 February–3 March, 2011 (abstract 523).
- bSimoneau, B.; Amad, M.; Bailey, M. D.; Bethell, R.; Bhardwaj, P. K.; Bilodeau, F.; Bonneau, P.; Bös, M.; Bousquet, Y.; Brochu, C.; Carson, R.; Chabot, C.; Cordingley, M.; Coulombe, R.; Duan, J.; Edwards, P.; Fader, L.; Faucher, A.M.; Fenwick, C.; Garneau, M.; Halmos, T.; Jakalian, A.; Kawai, S.; Landry, S.; Laplante, S.; Malenfant, E.; Mason, S.; Morin, S.; Parisien, M.; Pesant, M.; Poupart, M.A.; Tsantrizos, Y.; Wernic, D.; Yoakim, C.Identification of Novel Non-Catalytic Site Integrase Inhibitors (NCINIs) of LTR DNA 3′ Processing.24th International-Conference on Antiviral Research, Sofia, Bulgaria, May 8–11th, 2011, (Late Breaker abstract).
- Feng L., 2013, J. Biol. Chem., 288, 15813, 10.1074/jbc.m112.443390 · DOI · Paper page
Cited by
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
Modulation of Protein–Protein Interactions for the Development of Novel Therapeutics
Petta, I., Lievens, S., Libert, C., Tavernier, J., & De Bosscher, K. (2016) · Molecular Therapy · doi:10.1038/mt.2015.214 · Cited by 240
Lesbats, P., Engelman, A. N., & Cherepanov, P. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00125 · Cited by 233
Hindmarsh, P., & Leis, J. (1999) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.63.4.836-843.1999 · Cited by 202
da Cunha, J., Maselli, L. M. F., Stern, A. C. B., Spada, C., & Bydlowski, S. P. (2015) · World Journal of Virology · doi:10.5501/wjv.v4.i2.56 · Cited by 167
Metadata
- Authors
- Fader, L. D., Malenfant, E., Parisien, M., Carson, R., Bilodeau, F., Landry, S., Pesant, M., Brochu, C., Morin, S., Chabot, C., Halmos, T., Bousquet, Y., Bailey, M. D., Kawai, S. H., Coulombe, R., LaPlante, S., Jakalian, A., Bhardwaj, P. K., Wernic, D., Schroeder, P., Amad, M., Edwards, P., Garneau, M., Duan, J., Cordingley, M., Bethell, R., Mason, S. W., Bös, M., Bonneau, P., Poupart, M.-A., Faucher, A.-M., Simoneau, B., Fenwick, C., Yoakim, C., & Tsantrizos, Y.
- Affiliations
- Boehringer Ingelheim (Canada) (CA)
- Research and Development, Boehringer Ingelheim (Canada) Ltd., 2100 Cunard Street, Laval, Québec H7S 2G5, Canada
- Corresponding author
- Fader, Lee D.
- ORCID
- Venue
- ACS Medicinal Chemistry Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-01-28
- Volume
- 5
- Issue
- 4
- Pages
- 422-427
- ISSN
- 1948-5875 (ISSN-L)
- PMC
- PMC4027581
- OpenAlex
- W2000546717
- Cited by
- 178
- References
- 23
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 13 · 2023: 15 · 2022: 12 · 2021: 15 · 2020: 19 · 2019: 17 · 2018: 12 · 2017: 10 · 2016: 20 · 2015: 11 · 2014: 9
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- ACS Medicinal Chemistry Letters (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- HIV-1 integrase, antiviral drug discovery, hit-to-lead optimization, metabolic stability, lead optimization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1. https://app.cochat.ai/papers/10.1021/ml500002n
- The paper
- Fader, L. D., Malenfant, E., Parisien, M., Carson, R., Bilodeau, F., Landry, S., Pesant, M., Brochu, C., Morin, S., Chabot, C., Halmos, T., Bousquet, Y., Bailey, M. D., Kawai, S. H., Coulombe, R., LaPlante, S., Jakalian, A., Bhardwaj, P. K., Wernic, D., . . . Tsantrizos, Y. (2014). Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1. ACS Medicinal Chemistry Letters. https://doi.org/10.1021/ml500002n
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.